Key result
Rivaroxaban is more effective than enoxaparin in reducing total and symptomatic VTE with similar bleeding rates in patients undergoing elective total hip or knee replacement.
Why the study?
Does rivaroxaban reduce total and symptomatic VTE compared to enoxaparin in patients undergoing elective total hip or total knee replacement?
Does rivaroxaban reduce total and symptomatic VTE compared to enoxaparin in patients undergoing elective total hip or total knee replacement?
Rivaroxaban is an effective oral alternative to enoxaparin for VTE prophylaxis in patients undergoing major orthopedic surgery.
May support rivaroxaban as oral VTE prophylaxis in hip/knee replacement; leaves open confirmation by prospective trials.
Venous thromboembolism (VTE) is a major cause of death in hospitalized patients. In particular, patients undergoing elective major lower-limb orthopaedic surgery are at high risk of developing post-operative VTE. Rivaroxaban, a new oral anticoagulant, has been shown to be more effective than enoxaparin in reducing total and symptomatic VTE with similar major and non-major bleeding rates in patients undergoing elective total hip or total knee replacement.
No takes yet. Share an insight, caveat, or question.
N Fassiadis (2009) conducted a review in Venous thromboembolism. Rivaroxaban vs. Enoxaparin was evaluated on Total and symptomatic VTE. Rivaroxaban is more effective than enoxaparin in reducing total and symptomatic VTE with similar bleeding rates in patients undergoing elective total hip or knee replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: